Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study

Xinran Ma, MSc, Ling Li, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, PhD, Jingjing Wu, Xudong Zhang, Xiaoyan Feng, Zhiyuan Zhou, Yu Chang, Zhaoming Li, MD PhD, Ken H. Young, Mingzhi Zhang

Blood (2019) 134 (Supplement_1): 2873.

https://doi.org/10.1182/blood-2019-127912

Published: 2019

Journal Articles

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Robert J. Kreitman, MD, Philippe Moreau, Martin Hutchings, MD, Anas Gazzah, MD, Jean-Yves Blay, MD PhD, Zev A. Wainberg, MD, Alexander Stein, MD, Sascha Dietrich, MD, Maja J.A. de Jonge, MD, Wolfgang Willenbacher, MD, Jacques De Greve, MD, Evgeny Arons, PhD, Farhad Ravandi, MD, Fatima Rangwala, Paul Burgess, Bijoyesh Mookerjee, Vivek Subbiah, MD

Blood (2018) 132 (Supplement 1): 391.

https://doi.org/10.1182/blood-2018-99-113135

Published: 2018

Journal Articles

Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study

Ling Li, MSPH, Sa Xiao, Ken H. Young, MD PhD, Lei Zhang, MD, Xin Li, MD, Xiaorui Fu, MDPhD, Zhaoming Li, MDPhD, Zhenchang Sun, MDPhD, Xudong Zhang, MDPhD, Jiaqin Yan, MDPhD, Feifei Nan, MDPhD, Yu Chang, Mengyuan Shi, graduate student, Mingzhi Zhang

Blood (2017) 130 (Supplement 1): 1548.

https://doi.org/10.1182/blood.V130.Suppl_1.1548.1548

Published: 2017

Journal Articles

Targeted Therapy in FLT3-ITD Positive Myeloid Sarcoma: Proof of Principle

Giovanni Grillo, MD, Elisa Zucchetti, MD, Barbara Forno, MD, Ivana Lotesoriere, MD, Elena Inzoli, MD, Roberto Cairoli, MD

Blood (2017) 130 (Supplement 1): 5061.

https://doi.org/10.1182/blood.V130.Suppl_1.5061.5061

Published: 2017

Journal Articles

Spatiotemporal Mapping of Erythroid, Stromal, and Osteogenic Niche Formation to Support Physiologic Red Cell Production in a Three-Dimensional Hollow Fibre Perfusion Bioreactor

Mark C. Allenby, MSc, Asma Tahlawi, MSc, Ruth Misener, PhD, Susana Brito dos Santos, MSc, Athanasios Mantalaris, PhD, Nicki Panoskaltsis, MD PhD

Blood (2016) 128 (22): 3885.

https://doi.org/10.1182/blood.V128.22.3885.3885

Published: 2016

Journal Articles

A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia

Amir T. Fathi, MD, Traci M. Blonquist, MS, Mark J. Levis, MD PhD, Daniela Hernandez, MD, Karen K. Ballen, MD, David E. Avigan, MD, Robin Joyce, MD, Malgorzata McMasters, MD, Emma Logan, Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Christine Connolly, Ashley M. Perry, BS, Christelle Joseph, Tina T. Som, Aura Y. Ramos, Donna S. Neuberg, ScD, Philip C. Amrein, MD

Blood (2016) 128 (22): 5218.

https://doi.org/10.1182/blood.V128.22.5218.5218

Published: 2016

Journal Articles

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Blood (2016) 128 (22): 480.

https://doi.org/10.1182/blood.V128.22.480.480

Published: 2016

Journal Articles

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Hiroto Inaba, MD PhD, John C Panetta, PhD, Daelynn R Buelow, PhD, Raul C. Ribeiro, MD, John R. Eckardt, MD, Sharyn D Baker, PharmD, PhD

Blood (2016) 128 (22): 3937.

https://doi.org/10.1182/blood.V128.22.3937.3937

Published: 2016

Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Elias Jabbour, Marina Konopleva, MD PhD, Miranda Lim, BSN, Sherry Pierce, BSN, BA, Susan O'Brien, MD, Bradley G. Somer, MD, Ana Tari, PhD, William Wierda, MD PhD, Srdan Verstovsek, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3801.

https://doi.org/10.1182/blood.V126.23.3801.3801

Published: 2015

Journal Articles

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Dusan Prevalsek, MD, Susanne Fritsch, MD, Max Hubmann, MD, Nicole Engel, MD, Anna-Katharina Zoellner, MD, Thomas Köhnke, MD, Veit Leonhard Bücklein, MD, Christoph Schulz, MD, Friederike Mumm, MD, Christina Theresa Rieger, MD, Georg Ledderose, MD, Hans-Joachim Stemmler, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2015) 126 (23): 4318.

https://doi.org/10.1182/blood.V126.23.4318.4318

Published: 2015

Journal Articles

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Jesse Keller, MD, Mark A Fiala, BS, CCRP, Jeevan Sekhar, Connie Ceriotti, Melissa Allen, Camille N. Abboud, MD, Keith E. Stockerl-Goldstein, MD, Tanya M Wildes, MD MSCI, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD

Blood (2014) 124 (21): 4731.

https://doi.org/10.1182/blood.V124.21.4731.4731

Published: 2014

Journal Articles

Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial

Blood (2014) 124 (21): 6.

https://doi.org/10.1182/blood.V124.21.6.6

Published: 2014

Journal Articles

Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD, PhD, Elias Jabbour, MD, Marina Konopleva, MD, PhD, Susan O'Brien, MD, Alfonso Quintas-Cardama, MD, Bradley G. Somer, MD, Ana Tari, PhD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2679.

https://doi.org/10.1182/blood.V122.21.2679.2679

Published: 2013

Journal Articles

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MSc, Helen Won, MS, Julie Teruya-Feldstein, MD, Michael Berger, PhD, Talal T Khawaja, BS, Mario E Lacouture, MD, Ross L. Levine, MD, Omar Abdel-Wahab, MD, Martin S Tallman, MD

Blood (2013) 122 (21): 2876.

https://doi.org/10.1182/blood.V122.21.2876.2876

Published: 2013

Journal Articles

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Anna-Katharina Zoellner, Susanne Fritsch, MD, Dusan Prevalsek, MD, Nicole Engel, MD, Roland Reibke, MD, Christina T Rieger, MD, PhD, Georg Ledderose, MD, Wolfgang Hiddemann, MD, Martin Dreyling, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2013) 122 (21): 4544.

https://doi.org/10.1182/blood.V122.21.4544.4544

Published: 2013

Journal Articles

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Johanna Tischer, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Max Hubmann, MD, Veit Bücklein, Anna K Zöllner, MD, Christoph Schulz, MD, Roland Reibke, MD, Nicole Engel, MD, Christina T Rieger, MD, PhD, Christoph Schmid, MD, PhD, Georg Ledderose, MD, Wolfgang Hiddemann, MD, PhD, Andreas Hausmann, MD

Blood (2012) 120 (21): 3071.

https://doi.org/10.1182/blood.V120.21.3071.3071

Published: 2012

Journal Articles

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Jan Moritz Middeke, MD, Stefani Parmentier, MD, Nael Alakel, MD, Markus Schaich, MD, Christian Thiede, Uwe Platzbecker, MD, Christoph Röllig, Mathias Hänel, MD, Gernot Stuhler, MD, Anke Morgner, MD, Uta Eulenstein, Gerhard Ehninger, Martin Bornhäuser, MD, Johannes Schetelig, MD

Blood (2012) 120 (21): 2017.

https://doi.org/10.1182/blood.V120.21.2017.2017

Published: 2012

Journal Articles

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Leonard T Heffner, MD, Sundar Jagannath, MD, Todd M Zimmerman, MD, Kelvin P Lee, MD, Jacalyn Rosenblatt, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Niklas Czeloth, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2012) 120 (21): 4042.

https://doi.org/10.1182/blood.V120.21.4042.4042

Published: 2012

Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),

Jorge E. Cortes, Guillermo Garcia-Manero, Farhad Ravandi, MBBS, Michael Andreef, MD, PhD, Gautam Borthakur, Elias Jabbour, Marina Konopleva, M.D., Ph.D., Susan o'Brien, Alfonso Quintas-Cardama, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3639.

https://doi.org/10.1182/blood.V118.21.3639.3639

Published: 2011

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Keren Osman, MD, Kristy L. Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, Jennifer MacLean, RN, OCN, Diane Winans, CCRP, Dominic Moore, PhD, John Strader, PA-C, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2011) 118 (21): 3985.

https://doi.org/10.1182/blood.V118.21.3985.3985

Published: 2011

NARROW

Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study

Targeted Therapy in FLT3-ITD Positive Myeloid Sarcoma: Proof of Principle

Spatiotemporal Mapping of Erythroid, Stromal, and Osteogenic Niche Formation to Support Physiologic Red Cell Production in a Three-Dimensional Hollow Fibre Perfusion Bioreactor

A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only